Amgen’s Anti-Anemia Drug OKd for Swiss Sale

Johnson & Johnson said it has received approval to start selling in Switzerland the anti-anemia drug erythropoetin developed by Amgen in Thousand Oaks.

Johnson & Johnson is licensed by Amgen to sell the drug in Europe under the name EPREX, with Amgen receiving about 10% of the net sales. Amgen is seeking approval from the Food and Drug Administration to sell the drug domestically under the name Epogen.